May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The CISTO study is the only going prospective study comparing radical cystectomy vs bladder-sparing options for high-grade NMIBC.

Clinical results offered at the recent meeting of the American Urological Association in Las Vegas signal that better treatments may lie ahead for non-muscle invasive bladder cancer.

Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.

Paula Griffin was told she had cancer of the bladder. The diagnosis led to her finally accepting that she was a trans woman. Paula recalls that, at the time of her diagnosis, she was “in denial” about ...

US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus ...

All men are encouraged to pay attention when visiting the toilet because according to one expert, one particular sign can be ...

Louise Thompson today spoke candidly about the serious health issues she's had to contend with since giving birth to her now ...

The following is a summary of “Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression,” published in the April 2025 issue of BMC ...

Researchers conducted a retrospective study to compare hyperthermic intravesical chemotherapy (HIVEC) using pirarubicin (THP) and Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive ...